SCHEMBL7647205

SCHEMBL7647205

C[CH]CS(=O)(=O)c1ccc(F)cc1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.42
PAX8 Q06710 1/20 0.42
ALDH1A1 P00352 3/20 0.42
CTSK P43235 1/20 0.42
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
MMP2 P08253 2/20 0.41
MMP9 P14780 2/20 0.41
MMP1 P03956 1/20 0.41
MMP8 P22894 1/20 0.41
MMP13 P45452 1/20 0.41
MEN1 O00255 1/20 0.40
PKM P14618 1/20 0.40
CYP19A1 P11511 1/20 0.40
HSD11B1 P28845 1/20 0.40
MMP14 P50281 1/20 0.39
PTGS2 P35354 2/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4012964 0.79 KMT2A (0.44) KMT2APAX8ALDH1A1CTSKCA1
Chloromethane SCHEMBL27767488 0.79 ALDH1A1 (0.42) KMT2APAX8ALDH1A1CTSKCA1
SCHEMBL10584024 0.78 PSIP1 (0.60) KMT2AALDH1A1CTSKCA1CA2
Fluoresone SCHEMBL24999 0.78 PSIP1 (0.58) KMT2APAX8ALDH1A1CA1CA2
SCHEMBL7650922 0.77 NFE2L2 (0.42) KMT2AALDH1A1CA1CA2MEN1
SCHEMBL3256270 0.75 PLCG1 (0.58) KMT2APAX8ALDH1A1CA1CA2
SCHEMBL7648143 0.75 CA1 (0.50) KMT2AALDH1A1CA1CA2MMP2
SCHEMBL27746457 0.75 HTR2A (0.49) CTSKCA1CA2MMP2MMP9
SCHEMBL27765082 0.74 CTSK (0.42) KMT2APAX8ALDH1A1CTSKCA1
SCHEMBL9704701 0.73 CA1 (0.46) KMT2APAX8ALDH1A1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6486173-B2 SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-26 US claimed
US-20010041714-A1 5-HT7 receptor antagonists CAIN GARY A (US) 2001-11-15 US claimed
US-6486173-B2 SEROTONIN-7 (5-HT7); TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS SLEEP DISORDERS, DEPRESSION AND SCHIZOPHRENIA; FOR EXAMPLE 1,3-DIHYDRO-2-((4-(4-FLUOROPHENYL)-4-OXOBUTYL))ISOINDOLE BRISTOL-MYERS SQUIBB PHARMA COMPANY 2002-11-26 US disclosed
US-20010041714-A1 5-HT7 receptor antagonists CAIN GARY A (US) 2001-11-15 US disclosed
US-6239143-B1 TREATMENT CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, SLEEP DISORDERS, AND SCHIZOPHRENIA. DUPONT PHARMACEUTICALS COMPANY 2001-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010041714-A1 5-HT7 receptor antagonists HTR7, HTR5A, HTR1A KMT2A 3243/4885PAX8 3358/4885ALDH1A1 2592/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.